Intervention not reported
Response  · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Overall survival · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Relapse‐free survival · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Adverse events · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Quality of life · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Cost of intervention per month · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Response · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Overall survival · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Failure‐free survival · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Adverse events · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Quality of life · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Cost of intervention per month · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review